• Human IgM memory B cells possess immunoregulatory properties analogous to transitional B cells.
Introduction
Interleukin-10 (IL-10)-producing B cells are defined by an important set of regulatory functions that could be harnessed for therapeutic purposes. 1 Designated regulatory B cells (Bregs) by Mizoguchi et al, 2, 3 these cells can suppress inflammatory responses in experimental autoimmune encephalomyelitis, 4 collagen-induced arthritis, 5 and colitis, 3 and were recently implicated in the generation and maintenance of T-regulatory (Treg) cells in the periphery. 6 A number of Breg phenotypic markers have been identified in murine models, 7, 8 but exclusive reliance on phenotypic markers to distinguish between pathogenic and regulatory B cells can produce conflicting results, so that assays for functional properties such as IL-10 production are required to identify Bregs in a definitive, reproducible manner. 1, 9 Given the large gaps in understanding Breg phenotypic markers as they relate to immunosuppressive function, it is clear that more detailed investigation of the Breg "signature" is needed to permit meaningful exploration of therapies based on B cells with regulatory potential.
The study of human Bregs, which share many functional characteristics with murine Bregs, 10, 11 has been largely limited to IL-10-producing immature/transitional B cells in a small group of autoimmune diseases, including systemic lupus erythematous, 10 immune thrombocytopenia, 12 active chronic sarcoidosis, 13 and multiple sclerosis.
14 CD27 1 CD24 hi B cells have also been shown to modulate the monocyte innate immune response by suppressing their ability to produce tumor necrosis factor (TNF)-a in vitro, 10, 11 although evidence for their direct suppression of T-cell proliferation is lacking. Moreover, despite compelling evidence that human Breg cells can function as modulators of autoimmune disorders, 10, 12 very little is known about their activities in chronic graft-versus-host disease (cGVHD), where CD4 1 CD25 1 Tregs have attracted the most attention. [15] [16] [17] Chronic GVHD remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), and the prognosis for patients who fail to respond to corticosteroids is historically poor; hence, new therapies for this disorder are urgently needed. The pathogenesis of cGVHD is poorly understood, although it clearly resembles an autoimmune disease both clinically and pathologically. Multiple autoantibodies are often detected in patients with cGVHD, 18 suggesting a critical breakdown in peripheral B-cell tolerance and insufficient immune regulation after allogeneic HSCT. Indeed, B cells isolated from patients with cGVHD are typically activated with increased signaling through the AKT and ERK There is an Inside Blood Commentary on this article in this issue.
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pathways. 19 Thus, using B cells from both normal healthy donors and patients undergoing allogeneic HSCT, we sought to identify IL-10-producing cells with immunosuppressive properties within discrete B-cell subpopulations in peripheral blood (PB).
Our results demonstrate the presence of IL-10-producing Bregs with Treg-independent immunosuppressive functions in both the IgM memory (CD19 1 IgM 1 CD27 1 ) and transitional (CD19 1 CD24 hi CD38 hi ) B-cell subsets in healthy donors. Moreover, the regulatory function of these human Bregs against T cells required cell-cell contact as well as IL-10 production. Unlike Breg cells from healthy donors, those from cGVHD patients showed impaired IL-10 production when activated by CD40L, suggesting that infusion of donor-derived regulatory B cells may be used to minimize damage caused by active cGVHD and to reduce the risk of cGVHD development.
Material and methods

Patients and controls
All samples were collected patients gave written informed consent according to the local ethics policy guidelines and the Declaration of Helsinki.
Human cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated by densitygradient-separation (Lymphoprep) and cryopreserved in 20% dimethyl sulfoxide. B-cell subsets were sorted by FACSAria (Becton Dickinson) using CD19-PC7 (Immunotech), CD27-FITC (DakoCytomation), IgM-PerCP-Cy5.5, CD24-FITC (Biolegend), and CD38-PECy7 (ebioscience) antibodies. CD4
1
T cells and CD19
1 B cells were isolated by magnetic-bead purification (Miltenyi Biotic Ltd.). For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From antibodies. All data were acquired using BD-FACSCalibur (Becton Dickinson) and analyzed with FlowJo software.
Cell culture
CD40L-transfected L cells and nontransfected control fibroblasts (kindly provided by Dr Wagner, Imperial College, London, United Kingdom) were grown in RPMI 1640/10% fetal calf serum. For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From and CD4-PerCP, fixed/permeabilized, and followed by IFN-g-FITC and TNF-a-APC antibodies (all BD Biosciences).
Cytokine detection
Transwell cultures
CFSE
1 CD4 1 T cells were either directly added to sort-purified B-cell subsets at a ratio of 1:1 or placed in transwell chambers (Millicell, 1.0 mm; Millipore). After 96 hours in the presence of anti-CD3/CD28 Dynabeads (Life Technologies), cultured cells were harvested and analyzed by flow cytometry.
Blocking experiments
Purified B cells and T cells were cocultured and stimulated with anti-CD3/ anti-CD23 Dynabeads in the presence or absence of 5 mg/mL of anti-IL-10 (JEs#-9D7), anti-IL-10 receptor (3F9), anti-CD80 (10 mg/mL), anti-CD86 (10 mg/mL) (IT2.2), or antitransforming growth factor (TGF)-b (2 mg/mL) (TB21).
Statistics
All values are expressed as medians and ranges. Statistical significance was assessed with Prism software (GraphPad) by unpaired or paired 2-tailed Student t test analysis and by nonparametric 2-way analysis of variance (ANOVA), as appropriate. P # .05 was considered statistically significant. IL-10 production has long been considered a defining trait of Bregs. 9 Thus we applied intracellular staining for IL-10 together with a panel of surface antibodies to PBMCs from 10 healthy donors ( Figure 1A ). The PBMCs had been cultured with irradiated fibroblasts transfected with CD40-ligand (L cells) for 15 hours, because this duration of stimulation was found to be optimal for IL-10 production without the risk of undue changes in the overall B-cell phenotype (data not shown). IL- To discover whether IL-10-producing B cells are enriched within any of the commonly recognized B-cell subsets in PB, 20 we measured IL-10 concentrations in the supernatants derived from sort-purified CD19 Figure 1D ). These results underscore the regulatory capacity of immature transitional B cells (CD19 1 CD24 hi CD38 hi ), first described by Blair et al, 10 and support IgM memory B cells (CD19 (Figure 2A-C) , and these effects were cell dose-dependent ( Figure 2D ). They were also consistent with the ability of the transitional and IgM memory subsets to significantly suppress IFN-g, TNF-a, and IL-2 production by CD4 1 T cells in culture, whereas neither the naïve nor the switched memory subset showed this capacity ( Figure 2E-F) . We further compared the suppressive capacity of IgM memory and transitional B cells with that of Tregs, defined as CD4 1 CD25 hi CD127 lo . In experiments in which magnetically purified Tregs from 7 healthy volunteers were cocultured with autologous CD4
1 T cells at a 1:1 ratio, and the cultured cells were stimulated with anti-CD3/ anti-CD28 beads, the inhibition of T-cell proliferation and IFN-g production by transitional and IgM memory B cells was comparable with that by Tregs ( Figure 2G-H The suppressive capability of murine Bregs appears to be mediated by both the secretion of IL-10 and direct contact with CD4 1 T cells. 2, 3, 7, 10 It is still unclear, however, whether similar direct cellcell contact contributes to human Breg-mediated T-cell suppression. We therefore performed transwell experiments, in which transitional and IgM memory B cells were either in direct contact or separated from anti-CD3/anti-CD28-stimulated and CFSE-stained CD4 
67.7% [52.5-88.7] [P 5
.03], respectively, n 5 4), although this effect was not complete compared with the positive control ( Figure 4A-B) . Thus, we next asked whether a combination of IL-10 blockade and abrogation of direct cell-cell contact could entirely eliminate the suppressive effect of candidate Bregs on CD4 1 T-cell proliferation.
In experiments in which IL-10 and IL-10 receptor (IL-10R) mAbs were added to the sort-purified transitional and IgM memory B cells in a transwell setting, IL-10 blockade alone did not fully reverse the suppressive effect of either sort-purified transitional or IgM memory B cells on the proliferation of CD4 1 T cells. Subsequent addition of IL-10 and IL-10R Abs in a transwell setting essentially abolished the suppression of CD4 1 T-cell proliferation ( Figure 4C ).
Finally, we tested the contribution of CD80 and CD86 costimulatory signaling to the suppressive capacity of sort-purified transitional or IgM memory B-cell subsets, prompted by evidence from both murine and human B-cell experimental systems. 7, 10 The addition of blocking antibodies against the CD80 or CD86 molecules individually did not reverse the suppressive activity of IgM memory and transitional B cells (data not shown); however, blocking antibodies against the 2 molecules together partially inhibited the ability of both transitional and IgM memory B cells to suppress the proliferation of CD4 1 T cells ( Figure 5A ). Even though blocking mAbs against IL-10/IL-10R or CD80/CD86 individually failed to completely reverse the suppressive capacity of transitional and IgM memory B cells ( Figure 5B ), this end point was achieved with a combination of cell-cell contact blocking (with either a transwell block or CD80/CD86 antibodies) and antibodies to IL-10/IL-10R ( Figure 5C ). Thus, the suppressive effect of human Bregs depends on IL-10 production and cell-cell contact involving CD80 and CD86, consistent with findings in murine experimental models. 7 However, the suppressive effect of human transitional and IgM memory B cells was independent of CD80 cointeraction with the inhibitory receptor PD-1 expressed on T cells (data not shown).
To determine whether soluble CD40L is the trigger for IL-10 production in the transwell setting, we measured the levels of soluble CD40L in the supernatant by enzyme-linked immunosorbent assay. Soluble CD40L is naturally secreted by activated T cells 21 and can induce IL-10 production by B cells. 22 As is shown in supplemental Figure 4 , soluble CD40L was present in the cocultures with CD3/ CD28-activated CD4 1 T cells. We propose that soluble CD40L can cross the membrane and induce IL-10 production by transitional and IgM memory B cells to mediate T-cell suppression.
Suppressive effect of IgM memory and transitional B cells in vitro is independent of Treg activity
To test whether the suppressive effects of IL-10 1 transitional and Figure 3 ).
Bregs are deficient in patients with cGVHD
Results presented in Figure 2 , showing that IgM memory and transitional B-cell subsets can suppress CD4 1 T-cell proliferation and effector function, suggest that cGVHD might arise partly from a deficiency in either B-cell subsets or both. To assess this possibility, we examined 11 patients with cGVHD (supplemental Table 1 ), 11 without cGVHD and 12 healthy controls; the 2 patient groups had similar clinical characteristics (Table 1) . Those receiving high-dose steroids (.0.75 mg/kg prednisone) at the time of sampling or those who had received rituximab for any reason were excluded. Chronic GVHD status at the time of sample collection was classified according to published criteria. 23, 24 In keeping with previous reports, [25] [26] [27] Acute GVHD* Grade 0 7 (64) 3 (27) .37
Grades I-II 3 (27) 5 (46) Grades III-IV 1 (9) 3 (27) Donor lymphocyte infusions* The cohort includes patients who had received reduced intensity or myeloablative conditioning, followed by bone marrow or mobilized PB stem cell grafts. Those receiving high-dose steroids (.0.75 mg/kg prednisone) at the time of sampling or those who had received rituximab for any reason were excluded. cGVHD status at the time of sample collection was classified according to the National Institutes of Health cGVHD Consensus Criteria and modified Seattle Criteria for limited-vs-extensive disease. Eleven patients who were at a median of 14 months (range 11-37) posttransplant had active cGvHD (limited or extensive), whereas 11 patients who were 11 months (range 3-96) posttransplant lacked any history of cGVHD after HSCT. None of the no-cGVHD patients was on immunosuppressive therapy at the time of PB collection. All clinical characteristics, including age, sex, type of transplant, and underlying hematologic malignancy, were similar in patients with or without active cGVHD.
*n (%).
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B-cell responses may also be defective in patients with cGVHD. We therefore stimulated PBMCs from the same subjects reported in Table 1 and 12 healthy controls with irradiated L cells at a ratio of 1:10 for 48 hours, asking whether B cells from cGVHD patients had impaired IL-10 production when activated through CD40L followed by PMA1ionomycin stimulation. As is shown in Figure 6A 
Discussion
Regulation of the delicate balance between effector T-cell activities against invading pathogens and the tolerance of self-and environmental antigens has been largely ascribed to regulatory T cells. 15 of these subsets relies mainly on IL-10. Recombinant IL-10 has been tried unsuccessfully as a therapeutic measure against some autoimmune diseases such as Crohn disease, rheumatoid arthritis, and psoriasis. 36 Similarly, in our studies, exogenous addition of IL-10 to cocultures of naïve or switched memory B cells failed to induce CD4 1 T-cell suppression to the same extent as is seen with transitional and IgM memory B cells, indicating that cell-cell contact may be required for IL-10 to deliver optimal immune-regulatory signals. Indeed, transwell experiments and C80/86 blockade confirmed that such contact is needed for full exertion of IgM memory and transitional B-cell suppressive activity against CD4
1
T cells, although we found that the suppressive effect of these 2 subsets was independent of CD80 interaction with the inhibitory receptor PD-1 expressed on T cells (data not shown). The B cells in patients with cGVHD display a spectrum of abnormalities, including aberrant expression or function of key signaling molecules, costimulatory pathways, cytokines, and perturbations in developmental B-cell subsets. 37 These defects, together with the numerical and functional alterations of Tregs in cGVHD, 17 led us to propose that human Bregs might be similarly affected in this disease. Indeed, a recent study showed an important role for Bregs in protection against a murine model of cGVHD. 38, 39 In addition, previously published work supports a role for IL-10 deficiency in this disease. [40] [41] [42] We report that unlike healthy B cells, those from cGVHD patients display impaired IL-10 production when activated with CD40. These findings are consistent with the observation that in SLE, Breg cells are refractory to CD40 engagement. 10 Such defects carry a number of implications, because the CD40L-CD40 axis is crucial for B-cell proliferation, immunoglobulin class switching, germinal center development, and the survival of memory B cells. 43 However, because of the profound lymphopenia that characterizes the majority of patients with cGVHD, and the small volumes of PB available from patients with active cGVHD, it will still be necessary to directly test the suppressive capacity of purified IgM memory and transitional B cells derived from cGVHD patients (using coculture assays with CD4 1 T cells).
As a result of the impaired production of IL-10, the ratio of IL-10 1 B cells to IFN-g 1 CD4 1 T cells was significantly lower in cGVHD patients compared with the no-cGVHD group, which implies an imbalance between the regulatory B-cell and effector T-cell compartments analogous to that recognized with Tregs during the development of cGVHD. 28 Our findings therefore support a broader than expected deficit, involving both Breg and Treg cells, in the immune-regulated network that is involved in the control of cGVHD, and may partly explain the observations of persistent B-cell activation 19, 44 and autoimmune phenomena 45 that have been described in treatment-resistant cGVHD patients.
That some cGVHD patients, 46 but not others, respond to rituximab suggests that B cells may have variable roles in this disease. CD20 is expressed equally on both IL-10-producing and IL-10-negative B cells. Hence, B-cell depletion by rituximab is likely to deplete both Bregs and pathogenic B cells involved in cGVHD. One could therefore speculate For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From that B-cell depletion might improve cGVHD in cases in which effector B cells play a major role in the complex development of the disease, but not where Breg deficiency is the predominant component of the disease process. Thus, our data support future investigation of regulatory B cell-based therapy to tip the scales in favor of immune regulation so that cGVHD is either prevented or attenuated.
